Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
78
GALNF Quote, Financials, Valuation and Earnings
Last price:
$116.19
Seasonality move
:
0%
Day range:
$116.19 - $116.19
52-week range:
$75.25 - $116.19
Dividend yield:
1.21%
P/E ratio:
26.13x
P/S ratio:
1.25x
P/B ratio:
2.07x
Volume:
--
Avg. volume:
83
1-year change:
54.41%
Market cap:
$5.8B
Revenue:
$4.5B
EPS (TTM):
$4.45
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GALNF
Galenica AG
|
-- | -- | -- | -- | -- |
|
ACIU
AC Immune SA
|
$994.8K | -$0.22 | 18.61% | -6.92% | $9.01 |
|
ADXN
Addex Therapeutics Ltd.
|
$242.8K | -- | 2.35% | -- | $30.00 |
|
CRSP
CRISPR Therapeutics AG
|
$9M | -$1.29 | -89.16% | -180.62% | $81.33 |
|
ONC
BeOne Medicines Ltd.
|
$1.4B | $0.86 | 29.38% | -70.04% | $400.06 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GALNF
Galenica AG
|
$116.19 | -- | $5.8B | 26.13x | $1.40 | 1.21% | 1.25x |
|
ACIU
AC Immune SA
|
$3.13 | $9.01 | $314.9M | -- | $0.00 | 0% | 61.04x |
|
ADXN
Addex Therapeutics Ltd.
|
$8.20 | $30.00 | $10.1M | 0.77x | $0.00 | 0% | 37.51x |
|
CRSP
CRISPR Therapeutics AG
|
$56.71 | $81.33 | $5.4B | -- | $0.00 | 0% | 129.35x |
|
ONC
BeOne Medicines Ltd.
|
$311.73 | $400.06 | $34.5B | 599.83x | $0.00 | 0% | 6.96x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GALNF
Galenica AG
|
-- | -0.373 | -- | 0.86x |
|
ACIU
AC Immune SA
|
6.95% | 3.999 | 2.01% | 1.10x |
|
ADXN
Addex Therapeutics Ltd.
|
0.61% | 2.172 | 0.5% | 1.91x |
|
CRSP
CRISPR Therapeutics AG
|
9.92% | 3.188 | 3.47% | 16.13x |
|
ONC
BeOne Medicines Ltd.
|
31.57% | 0.334 | 5.05% | 2.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GALNF
Galenica AG
|
-- | -- | 13.26% | 13.26% | -- | -- |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
ADXN
Addex Therapeutics Ltd.
|
-- | -$869.9K | -73.49% | -73.84% | -1403.07% | -$687.4K |
|
CRSP
CRISPR Therapeutics AG
|
-$60.6M | -$132.1M | -23.42% | -26.17% | -14854.78% | -$84.7M |
|
ONC
BeOne Medicines Ltd.
|
$1.2B | $163.3M | 1.43% | 1.92% | 11.55% | $355.1M |
Galenica AG vs. Competitors
-
Which has Higher Returns GALNF or ACIU?
AC Immune SA has a net margin of -- compared to Galenica AG's net margin of -1688.87%. Galenica AG's return on equity of 13.26% beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital GALNFGalenica AG-- -- $1.8B ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About GALNF or ACIU?
Galenica AG has a consensus price target of --, signalling downside risk potential of --. On the other hand AC Immune SA has an analysts' consensus of $9.01 which suggests that it could grow by 188.23%. Given that AC Immune SA has higher upside potential than Galenica AG, analysts believe AC Immune SA is more attractive than Galenica AG.
Company Buy Ratings Hold Ratings Sell Ratings GALNFGalenica AG0 0 0 ACIUAC Immune SA4 0 0 -
Is GALNF or ACIU More Risky?
Galenica AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.243%.
-
Which is a Better Dividend Stock GALNF or ACIU?
Galenica AG has a quarterly dividend of $1.40 per share corresponding to a yield of 1.21%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galenica AG pays 62.66% of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend. Galenica AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GALNF or ACIU?
Galenica AG quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $1.2M. Galenica AG's net income of -- is lower than AC Immune SA's net income of -$19.8M. Notably, Galenica AG's price-to-earnings ratio is 26.13x while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galenica AG is 1.25x versus 61.04x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GALNFGalenica AG1.25x 26.13x -- -- ACIUAC Immune SA61.04x -- $1.2M -$19.8M
-
Which has Higher Returns GALNF or ADXN?
Addex Therapeutics Ltd. has a net margin of -- compared to Galenica AG's net margin of -3178.71%. Galenica AG's return on equity of 13.26% beat Addex Therapeutics Ltd.'s return on equity of -73.84%.
Company Gross Margin Earnings Per Share Invested Capital GALNFGalenica AG-- -- $1.8B ADXNAddex Therapeutics Ltd.-- -$2.10 $7.5M -
What do Analysts Say About GALNF or ADXN?
Galenica AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Addex Therapeutics Ltd. has an analysts' consensus of $30.00 which suggests that it could grow by 265.85%. Given that Addex Therapeutics Ltd. has higher upside potential than Galenica AG, analysts believe Addex Therapeutics Ltd. is more attractive than Galenica AG.
Company Buy Ratings Hold Ratings Sell Ratings GALNFGalenica AG0 0 0 ADXNAddex Therapeutics Ltd.0 0 0 -
Is GALNF or ADXN More Risky?
Galenica AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Addex Therapeutics Ltd. has a beta of 1.573, suggesting its more volatile than the S&P 500 by 57.32%.
-
Which is a Better Dividend Stock GALNF or ADXN?
Galenica AG has a quarterly dividend of $1.40 per share corresponding to a yield of 1.21%. Addex Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galenica AG pays 62.66% of its earnings as a dividend. Addex Therapeutics Ltd. pays out -- of its earnings as a dividend. Galenica AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GALNF or ADXN?
Galenica AG quarterly revenues are --, which are smaller than Addex Therapeutics Ltd. quarterly revenues of $62K. Galenica AG's net income of -- is lower than Addex Therapeutics Ltd.'s net income of -$2M. Notably, Galenica AG's price-to-earnings ratio is 26.13x while Addex Therapeutics Ltd.'s PE ratio is 0.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galenica AG is 1.25x versus 37.51x for Addex Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GALNFGalenica AG1.25x 26.13x -- -- ADXNAddex Therapeutics Ltd.37.51x 0.77x $62K -$2M
-
Which has Higher Returns GALNF or CRSP?
CRISPR Therapeutics AG has a net margin of -- compared to Galenica AG's net margin of -11973.12%. Galenica AG's return on equity of 13.26% beat CRISPR Therapeutics AG's return on equity of -26.17%.
Company Gross Margin Earnings Per Share Invested Capital GALNFGalenica AG-- -- $1.8B CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B -
What do Analysts Say About GALNF or CRSP?
Galenica AG has a consensus price target of --, signalling downside risk potential of --. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.33 which suggests that it could grow by 43.42%. Given that CRISPR Therapeutics AG has higher upside potential than Galenica AG, analysts believe CRISPR Therapeutics AG is more attractive than Galenica AG.
Company Buy Ratings Hold Ratings Sell Ratings GALNFGalenica AG0 0 0 CRSPCRISPR Therapeutics AG12 10 1 -
Is GALNF or CRSP More Risky?
Galenica AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.738, suggesting its more volatile than the S&P 500 by 73.75%.
-
Which is a Better Dividend Stock GALNF or CRSP?
Galenica AG has a quarterly dividend of $1.40 per share corresponding to a yield of 1.21%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galenica AG pays 62.66% of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend. Galenica AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GALNF or CRSP?
Galenica AG quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of $889K. Galenica AG's net income of -- is lower than CRISPR Therapeutics AG's net income of -$106.4M. Notably, Galenica AG's price-to-earnings ratio is 26.13x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galenica AG is 1.25x versus 129.35x for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GALNFGalenica AG1.25x 26.13x -- -- CRSPCRISPR Therapeutics AG129.35x -- $889K -$106.4M
-
Which has Higher Returns GALNF or ONC?
BeOne Medicines Ltd. has a net margin of -- compared to Galenica AG's net margin of 8.84%. Galenica AG's return on equity of 13.26% beat BeOne Medicines Ltd.'s return on equity of 1.92%.
Company Gross Margin Earnings Per Share Invested Capital GALNFGalenica AG-- -- $1.8B ONCBeOne Medicines Ltd.83.86% $1.09 $6B -
What do Analysts Say About GALNF or ONC?
Galenica AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $400.06 which suggests that it could grow by 28.34%. Given that BeOne Medicines Ltd. has higher upside potential than Galenica AG, analysts believe BeOne Medicines Ltd. is more attractive than Galenica AG.
Company Buy Ratings Hold Ratings Sell Ratings GALNFGalenica AG0 0 0 ONCBeOne Medicines Ltd.18 1 1 -
Is GALNF or ONC More Risky?
Galenica AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.452, suggesting its less volatile than the S&P 500 by 54.771%.
-
Which is a Better Dividend Stock GALNF or ONC?
Galenica AG has a quarterly dividend of $1.40 per share corresponding to a yield of 1.21%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galenica AG pays 62.66% of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend. Galenica AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GALNF or ONC?
Galenica AG quarterly revenues are --, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. Galenica AG's net income of -- is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, Galenica AG's price-to-earnings ratio is 26.13x while BeOne Medicines Ltd.'s PE ratio is 599.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galenica AG is 1.25x versus 6.96x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GALNFGalenica AG1.25x 26.13x -- -- ONCBeOne Medicines Ltd.6.96x 599.83x $1.4B $125M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
GLTO alert for Dec 26
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Buy
80
TVTX alert for Dec 26
Travere Therapeutics, Inc. [TVTX] is down 1.54% over the past day.
Sell
27
CDNAF alert for Dec 26
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
